2. Search Result
Search Result
Results for "

Nicotinamide

" in MedChemExpress (MCE) Product Catalog:

163

Inhibitors & Agonists

2

Fluorescent Dyes

8

Biochemical Assay Reagents

8

Peptides

1

MCE Kits

21

Natural
Products

7

Recombinant Proteins

15

Isotope-Labeled Compounds

7

Antibodies

1

Click Chemistry

4

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0150
    Nicotinamide
    Maximum Cited Publications
    89 Publications Verification

    Niacinamide; Nicotinic acid amide

    		 Environmental Pollutants Endogenous Metabolite Sirtuin HBV Organoid Cancer
    Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide
  • HY-F0004
    Fosribnicotinamide
    25+ Cited Publications

    β-Nicotinamide mononucleotide; β-NM; NMN

    		 Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide
  • HY-B0445
    NAD+
    40+ Cited Publications

    β-DPN; β-NAD; β-Nicotinamide Adenine Dinucleotide

    		 Endogenous Metabolite Metabolic Disease
    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.
    NAD+
  • HY-123033A
    Nicotinamide riboside chloride
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside Chloride, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside chloride
  • HY-137592
    Nicotinamide 1,N6-ethenoadenine dinucleotide

    ε-NAD

    		 Fluorescent Dye Phosphodiesterase (PDE) Glutamate Dehydrogenase (GLDH) Others
    Nicotinamide 1,N6-ethenoadenine dinucleotide (ε-NAD) is a fluorescent analog of NAD. Nicotinamide 1,N6-ethenoadenine dinucleotide can be cleaved by phosphodiesterase I (from C. adamanteus venom) and binds to bovine liver glutamate dehydrogenase. Nicotinamide 1,N6-ethenoadenine dinucleotide can serve as a substrate for G-ADP ribosylation of G proteins catalyzed by bacterial toxins. Nicotinamide 1,N6-ethenoadenine dinucleotide can be used as a fluorescent substrate for the study of ADP ribosylation reactions .
    Nicotinamide 1,N6-ethenoadenine dinucleotide
  • HY-B0445A
    NAD sodium
    40+ Cited Publications

    β-DPN sodium; β-NAD sodium; β-Nicotinamide Adenine Dinucleotide sodium

    		 Endogenous Metabolite Metabolic Disease
    NAD sodium is an orally effective cofactor and homeostatic regulator. NAD sodium can be reduced to β-nicotinamide adenine dinucleotide (NADH) during coupling with reactions that oxidize organic substrates. NAD sodium can be converted to β-nicotinamide adenine dinucleotide (NADH) and passes to the inside of mitochondria, which indirectly generates ATP. NAD sodium can be used for the research of non-alcoholic fatty liver disease, obesity, and glucose intolerance .
    NAD sodium
  • HY-W010342
    6-Aminonicotinamide
    15+ Cited Publications

    		 NADPH Oxidase Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide
  • HY-B0150S
    Nicotinamide-d4
    1 Publications Verification

    Niacinamide-d4; Nicotinic acid amide-d4

    		 Sirtuin Endogenous Metabolite Neurological Disease Cancer
    Nicotinamide-d4 is the deuterium labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.
    Nicotinamide-d4
  • HY-175603
    NCGC00685960

    		Amine N-methyltransferase Cancer
    NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 <10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research, such as ovarian cancer, breast cancer, colon cancer .
    NCGC00685960
  • HY-113432
    Nudifloramide

    2PY

    		 Endogenous Metabolite PARP Metabolic Disease
    Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .
    Nudifloramide
  • HY-101407
    Nicotinamide N-oxide
    3 Publications Verification

    		 Oxidative Phosphorylation CXCR Drug Metabolite Endogenous Metabolite Inflammation/Immunology Endocrinology
    Nicotinamide N-oxide, an in vivo nicotinamide metabolite, is a potent, and selective antagonist of the CXCR2 receptor.
    Nicotinamide N-oxide
  • HY-126255
    SBI-797812
    2 Publications Verification

    		 NAMPT Metabolic Disease
    SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD +. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD + in mice .
    SBI-797812
  • HY-12793
    Padnarsertib
    3 Publications Verification

    KPT-9274

    		 PAK NAMPT Cancer
    Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
    Padnarsertib
  • HY-112584
    JBSNF-000088
    5+ Cited Publications

    6-MethoxyNicotinamide

    		 Amine N-methyltransferase Metabolic Disease
    JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .
    JBSNF-000088
  • HY-10079
    CHS-828
    4 Publications Verification

    GMX1778

    		 NAMPT Apoptosis Cancer
    CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
    CHS-828
  • HY-123033
    Nicotinamide riboside

    		Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside
  • HY-B0150R
    Nicotinamide (Standard)
    Maximum Cited Publications
    89 Publications Verification

    Niacinamide(Standard); Nicotinic acid amide (Standard)

    		 Reference Standards Endogenous Metabolite Sirtuin Cancer
    Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .
    Nicotinamide (Standard)
  • HY-W615108B
    β-Nicotinamide mononucleotide, reduced form disodium

    NMNH disodium

    		 Endogenous Metabolite Cancer
    β-Nicotinamide mononucleotide, reduced form (NMNH) disodium is an orally active reduced version of β-Nicotinamide mononucleotide (HY-F0004). β-Nicotinamide mononucleotide, reduced form disodium can significantly increase the levels of NAD + and NADH, inhibit glycolysis, the tricarboxylic acid cycle, and cell growth, with its effects being dependent on nicotinamide mononucleotide adenylyltransferase (NMNAT) .
    β-Nicotinamide mononucleotide, reduced form disodium
  • HY-151500
    JBSNF-000028 free base

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 free base
  • HY-124124
    N-Methylnicotinamide
    1 Publications Verification

    		 Endogenous Metabolite Drug Metabolite Cardiovascular Disease Metabolic Disease Cancer
    N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway .
    N-Methylnicotinamide
  • HY-P2804
    GAPDH, rabbit muscle
    1 Publications Verification

    GADPH; G3PDH; Glyceraldehyde phosphate dehydrogenase

    		 Endogenous Metabolite Others
    Glyceraldehyde phosphate dehydrogenase (EC 1.2.1.12) is the target of anti-thymocyte and anti-apoptotic agents. Glyceraldehyde phosphate dehydrogenase catalyzes the chain oxidation of reduced nicotinamide adenine dinucleotide by perhydroxyl radicals .
    GAPDH, rabbit muscle
  • HY-113472
    N-Methyl-4-pyridone-3-carboxamide

    		Drug Metabolite Others
    N-Methyl-4-pyridone-3-carboxamide (compound 4PY) is a final product of nicotinamide adenine dinucleotide (NAD) degradation .
    N-Methyl-4-pyridone-3-carboxamide
  • HY-157421
    Nampt activator-4

    		NAMPT Metabolic Disease
    Nampt activator-4 is an orally active NAMPT activator, with an EC50 of 58 nM and a Ka of 85.38 nM against human NAMPT. Nampt activator-4 effectively relieves the feedback inhibition of nicotinamide and NAD +, thereby enhancing enzymatic activity and significantly increasing intracellular NAD + levels. Nampt activator-4 exhibits moderate stability in human and mouse liver microsomes. Nampt activator-4 shows low to moderate inhibitory effects on cytochrome P450 (especially CYP3A4). Nampt activator-4 can be used for the research of type 2 diabetes and related metabolic disorders .
    Nampt activator-4
  • HY-P3185
    beta-Galactose dehydrogenase

    		Biochemical Assay Reagents Metabolic Disease
    Beta-galactose dehydrogenase is a selective catalyst for β-galactose. Under pH 8.6 conditions, beta-galactose dehydrogenase catalyzes the oxidation of β-galactose, produced by the hydrolysis of lactose by β-galactosidase, with nicotinamide adenine dinucleotide (NAD) to produce reduced nicotinamide adenine dinucleotide (NADH). Beta-galactose dehydrogenase specifically mediates this oxidation reaction for the quantitative detection of the substrate, used in the analysis of lactose concentration in samples such as breast milk .
    beta-Galactose dehydrogenase
  • HY-F0004S
    Fosribnicotinamide-d4

    β-Nicotinamide mononucleotide-d4; β-NM-d4; NMN-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide-d4
  • HY-138993A
    NNMT-IN-6 hydrochloride

    		Amine N-methyltransferase Cancer
    NNMT-IN-6 hydrochloride is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 hydrochloride inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 hydrochloride can be used for the research of oral cancer .
    NNMT-IN-6 hydrochloride
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-123033AR
    Nicotinamide riboside chloride (Standard)

    		Reference Standards Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside (chloride) (Standard) is the analytical standard of Nicotinamide riboside (chloride). This product is intended for research and analytical applications. Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
    Nicotinamide riboside chloride (Standard)
  • HY-123033C
    Nicotinamide riboside malate
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside malate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside malate
  • HY-151500B
    JBSNF-000028 hydrochloride

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 hydrochloride
  • HY-W093017
    4-Chloropyridine

    		Amine N-methyltransferase Others
    4-Chloropyridine is a NNMT (Nicotinamide N-methyltransferase) substrate and suicide inhibition-based protein labeling scaffold precursor.4-Chloropyridine undergoes NNMT-catalyzed pyridine nitrogen methylation to increase C4 electrophilicity, enabling aromatic nucleophilic substitution by NNMT cysteine C159 for covalent NNMT modification and inactivation.4-Chloropyridine can be used for the research of various cancers .
    4-Chloropyridine
  • HY-12628
    GNE-618
    2 Publications Verification

    		 NAMPT Cancer
    GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .
    GNE-618
  • HY-B0445B
    α-NAD

    α-Nicotinamide Adenine Dinucleotide

    		 Mitochondrial Metabolism Endogenous Metabolite Metabolic Disease
    α-NAD (α-Nicotinamide Adenine Dinucleotide) serves as a substrate for reninase, functions as an analog of β-NAD, affects the kinetics of NAD-dependent enzymes, and also plays a critical role as a cofactor in mitochondrial redox reactions .
    α-NAD
  • HY-W015815
    6-Methylnicotinamide

    		Endogenous Metabolite Neurological Disease
    6-Methylnicotinamide is a nicotinamide derivative. 6-methylnicotinamide is also an endogenous metabolite and its sudden increase in the acute stages of intracerebral hemorrhage (ICH) exacerbates neurological damages in rat model. 6-Methylnicotinamide can significantly enhance the coordination effect between acylamino and undercoordinated defective Pb 2+ cations. 6-Methylnicotinamide results in enhanced efficiency of perovskite solar cells to 24.33% with excellent environmental storage, heat, and light stabilities .
    6-Methylnicotinamide
  • HY-151193
    NNMT-IN-3

    		Amine N-methyltransferase Metabolic Disease Cancer
    NNMT-IN-3 (Compound 14) is a potent and selective nicotinamide N-methyltransferase (NNMT) inhibitor, with IC50 values of 1.1 nM and 0.4 μM in cell-free and cell-based assays, respectively. NNMT-IN-3 can be used in the research of diseases such as obesity, type 2 diabetes and cancer .
    NNMT-IN-3
  • HY-124124S
    N-Methylnicotinamide-d4

    		Isotope-Labeled Compounds Endogenous Metabolite Drug Derivative Cardiovascular Disease Metabolic Disease Cancer
    N-Methylnicotinamide-d4 is the deuterium labeled N-Methylnicotinamide (HY-124124). N-Methylnicotinamide is an endogenous metabolite with antithrombotic effect. N-Methylnicotinamide via production/release of prostacyclin inhibits arterial thrombosis development. N-Methylnicotinamide is also the N-methylation product from nicotinamide catalyzed by N-methyltransferase within nicotinate and nicotinamide metabolism pathway.
    N-Methylnicotinamide-d4
  • HY-124313
    1-Methyl-1,4-dihydronicotinamide

    		Reactive Oxygen Species (ROS) Others
    1-Methyl-1,4-dihydronicotinamide is a derivative of nicotinamide, with radical scavenging activity .
    1-Methyl-1,4-dihydronicotinamide
  • HY-131485
    3-Acetylpyridine adenine dinucleotide, 90%

    3-APAD, 90%; 3-Acetylpyridine NAD, 90%

    		 Lactate Dehydrogenase Metabolic Disease
    3-Acetylpyridine adenine dinucleotide, 90% is an analog of nicotinamide adenine dinucleotide (NAD). 33-Acetylpyridine adenine dinucleotide, 90% collaboratively inhibits Lactate Dehydrogenase (LDH) with bisulfite .
    3-Acetylpyridine adenine dinucleotide, 90%
  • HY-164690A
    Nicotinamide-guanine dinucleotide sodium

    		Endogenous Metabolite Metabolic Disease
    Nicotinamide-guanine dinucleotide sodium, a NAD sodium (HY-B0445A) analog, is an oxidized forms of nicotinamide guanine dinucleotide. Nicotinamide-guanine dinucleotide sodium serves as coenzymes for alcohol dehydrogenase (ADH) in vitro .
    Nicotinamide-guanine dinucleotide sodium
  • HY-116993
    N-(Hydroxymethyl)nicotinamide

    		Bacterial Infection
    N-(Hydroxymethyl)nicotinamide is an antimicrobic agent .
    N-(Hydroxymethyl)nicotinamide
  • HY-123033B
    Nicotinamide riboside tartrate
    20+ Cited Publications

    		 Sirtuin Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Nicotinamide riboside tartrate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
    Nicotinamide riboside tartrate
  • HY-B0150S2
    Nicotinamide-13C6

    Niacinamide-13C6; Nicotinic acid amide-13C6

    		 Endogenous Metabolite Sirtuin Neurological Disease Cancer
    Nicotinamide- 13C6 is the 13C-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.
    Nicotinamide-13C6
  • HY-F0004R
    Fosribnicotinamide (Standard)

    β-Nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004 ). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide (Standard)
  • HY-W250163
    NAD+ lithium
    40+ Cited Publications

    β-DPN lithium; β-NAD lithium; β-Nicotinamide Adenine Dinucleotide lithium

    		 Biochemical Assay Reagents Metabolic Disease
    NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
    NAD+ lithium
  • HY-10080
    Teglarinad chloride

    GMX1777; EB-1627

    		 NAMPT Cancer
    Teglarinad chloride (GMX1777) is a proagent of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis .
    Teglarinad chloride
  • HY-137672A
    2',3'-Cyclic NADP disodium

    2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate

    		 Phosphodiesterase (PDE) Calcium Channel Neurological Disease
    2',3'-Cyclic NADP disodium (2',3'-cNADP+; β-Nicotinamide adenine dinucleotide-2',3'-cyclic phosphate) is a substrate for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), an enzyme abundant in myelin. It has been used in a coupled enzyme assay to quantify CNP activity. 2',3'-Cyclic NADP disodium (5 μM) increases calcium overload-induced calcium release and prevents calcium-induced swelling in rat brain mitochondria.
    2',3'-Cyclic NADP disodium
  • HY-138993
    NNMT-IN-6

    		Amine N-methyltransferase Cancer
    NNMT-IN-6 is a selective nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 of 1.41 μM and a Kd of 5.55 μM. NNMT-IN-6 hydrochloride exhibits selectivity over PRMT1 and NSD2. NNMT-IN-6 inhibits cancer cell proliferation and reduces cellular N-methylnicotinamide (MNA) production. NNMT-IN-6 can be used for the research of oral cancer .
    NNMT-IN-6
  • HY-108701
    Nampt-IN-3

    		NAMPT HDAC Autophagy Apoptosis Cancer
    Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
    Nampt-IN-3
  • HY-B0150S1
    Nicotinamide-15N,13C3

    Niacinamide-15N,13C3; Nicotinic acid amide-15N,13C3

    		 Isotope-Labeled Compounds Endogenous Metabolite Sirtuin Neurological Disease Cancer
    Nicotinamide- 15N, 13C3 is the 13C-labeled and 15N-labeled Nicotinamide. Nicotinamide is a form of vitamin B3 that plays essential roles in cell physiology through facilitating NAD+ redox homeostasis and providing NAD+ as a substrate to a class of enzymes that catalyze non-redox reactions. Nicotinamide is an inhibitor of SIRT1.
    Nicotinamide-15N,13C3
  • HY-111367
    MS2734

    		Amine N-methyltransferase Neurological Disease Metabolic Disease Cancer
    MS2734 is a inhibitor of nicotinamide N-methyltransferase (NNMT). MS2734 potently inhibits the methyltransferase activity of human NNMT (hNNMT) with an IC50 value of 14 μM. MS2734 can be used for the study of obesity, diabetes, Parkinson's disease, and various cancers with high NNMT expression .
    MS2734

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: